FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a polypeptide specifically binding to CD3, as well as a nucleic acid encoding it. Said polypeptide comprises a CD3 binding domain with a reduced isoelectric point. Also, the expression vector and the host cell containing the aforementioned nucleic acid are disclosed. Also, the invention relates to a pharmaceutical composition for the treatment of cancer or an autoimmune disease, as well as to a method for treating a tumor expressing a prostate-specific membrane antigen using the above polypeptide.
EFFECT: invention makes it possible to efficiently bind both a T cell receptor complex on T cells and a tumor antigen to induce a target-dependent cytotoxicity, activation and proliferation of T cells.
60 cl, 27 dwg, 10 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEINS BINDING SPECIFIC MEMBRANE PROSTATE ANTIGEN, AND RELATED COMPOSITIONS AND METHODS | 2012 |
|
RU2632647C2 |
| 5T4 AND 4-1BB ANTIGEN-BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | 2018 |
|
RU2804458C2 |
| METHOD FOR SELECTION AND OBTAINING OF HIGHLY SELECTIVE AND MULTISPECIFIC TARGETING GROUPS WITH SPECIFIED PROPERTIES, INCLUDING AT LEAST TWO DIFFERENT BINDING GROUPS, AND THEIR APPLICATIONS | 2013 |
|
RU2639287C2 |
| BISPECIFIC ASYMMETRIC HETERODIMERS COMPRISING ANTI-CD3 CONSTRUCTS | 2013 |
|
RU2650868C2 |
| TRISPECIFIC BINDING MOLECULES, WHICH SPECIFICALLY BIND ANTIGENS OF A VARIETY OF MALIGNANT TUMORS, AND METHODS OF USING THEM | 2015 |
|
RU2718692C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| BISPECIFIC CHECKPOINT INHIBITORS ANTIBODIES | 2017 |
|
RU2767357C2 |
| BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
| PROTEIN COMPLEXES CONTAINING SUPERHELIX AND/OR BANDING, AND THEIR USE | 2010 |
|
RU2573915C2 |
| BISPECIFIC ANTIBODY AND ITS USE | 2019 |
|
RU2785292C2 |
